Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2064058
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to investigate the effect and the side effect profile of irinotecan and panitumumab administered every 3 weeks as 3rd line treatment for patients with metastatic colorectal cancer without KRAS mutations.
创建时间：
2008-11-15
